Type-2 diabetes mellitus related cardiovascular risk: New options for interventions to reduce risk and treatment goals
References (15)
- et al.
Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study
Lancet
(1997) - et al.
Epidemic of obesity in UK children
Lancet
(1999) - et al.
CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Lancet
(2004) VALUE: analysis of results
Lancet
(2004)- et al.
Lifetime costs of complications resulting from type 2 diabetes in the US
Diab Care
(2002) - et al.
Impact of diabetes on long-term survival after acute myocardial infarction
Diab Care
(2001)
There are more references available in the full text version of this article.
Cited by (14)
Hypertension and Dyslipidemia in Patients with Pre-Diabetes: Dietary and Other Therapies
2015, Glucose Intake and Utilization in Pre-Diabetes and Diabetes: Implications for Cardiovascular DiseaseVascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms
2014, Molecular MetabolismCitation Excerpt :Morbidity and mortality among people with diabetes mellitus are mostly triggered by premature cardiovascular disease (CVD) [1,2].
Effects of glyoxal or methylglyoxal on the metabolism of amino acids, lactate, glucose and acetate in the cerebral cortex of young and adult rats
2010, Brain ResearchCitation Excerpt :Cardiovascular disease is one of the main causes of mortality among diabetic patients (Hobbs, 2006).
Antagonizing the effects of dietary advanced glycation end products on endothelial dysfunction
2017, Dietary AGEs and their Role in Health and DiseaseVascular effects of dietary advanced glycation end products
2015, International Journal of Endocrinology
Copyright © 2006 Elsevier Ireland Ltd. All rights reserved.